Compare Invesco DB Agriculture Fund (DBA) vs Revvity Inc (RVTY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Invesco DB Agriculture Fund vs Revvity Inc — how do they compare? Invesco DB Agriculture Fund trades at $28.53 (market cap $1.32B), while Revvity Inc trades at $152.05 (market cap $16.98B). The key difference: Revvity Inc is far larger — about 12.9× Invesco DB Agriculture Fund's market cap, and Revvity Inc pays a 0.18% dividend while Invesco DB Agriculture Fund pays none. Which is the better fit depends on your goals — on Pluang, investors hold Invesco DB Agriculture Fund for 24 Days and Revvity Inc for 12 Days on average.
| DBA | RVTY | |
|---|---|---|
Market Cap | $1.32B | $16.98B |
Volume | 771,657 | 1,456,900 |
52-Week High | $29.49 | $157.36 |
52-Week Low | $25.44 | $82.26 |
Typical Hold Time | 24 Days | 12 Days |
Sector | — | Health |
Enterprise Value | — | $19.30B |
Dividend Yield | — | 0.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DBA (Invesco DB Agriculture Fund ETF) trades at $28.49, down 1.25% today but maintains strong year-to-date performance with 12.4% returns matching the S&P 500. The technical outlook remains bullish with moving averages signaling strength and ADX indicators confirming trend momentum. Recent news highlights agricultural ETF outperformance driven by weather risks, geopolitical tensions, and strong global demand for commodities.
The agricultural commodities exposure positions DBA for potential upside from supply chain disruptions and climate factors, though the 0.85% expense ratio and commodity volatility present risks. Analyst sentiment is mixed with Seeking Alpha maintaining a Hold rating while noting bullish technical consolidation near all-time highs since 2020.
RVTY trades at $153.60, up 0.2% today and near its 52-week high of $158.28 (Defense World, 2026-10-01). The stock shows a bullish technical trend with strong moving average signals and has beaten earnings estimates for three consecutive quarters. Recent developments include the launch of a CE-IVDR-certified T1D screening kit in Europe (Business Wire, 2026-09-24) and the acquisition of Human Cell Design to expand metabolic disease research tools (Business Wire, 2026-09-09).
The outlook is positive, supported by earnings momentum, strategic acquisitions, and analyst optimism. However, the stock trades at a premium valuation with a P/E of 73.15, and near-term risks include margin pressures in China and rich valuation limiting upside beyond consensus targets. Revenue stability but slight profit margin compression in 2026 warrants monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Invesco DB Agriculture Fund
The index, which is comprised of one or more underlying commodities ("index commodities"), is intended to reflect the agricultural sector. The fund pursues its investment objective by investing in a portfolio of exchange-traded futures.
Read more on DBA →About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →
